dc.contributor.author
Pedro-Botet, Juan
dc.contributor.author
Ascaso, Juan F.
dc.contributor.author
Barrios, Vivencio
dc.contributor.author
De la Sierra, Alejandro
dc.contributor.author
Escalada, Javier
dc.contributor.author
Millán, Jesús
dc.contributor.author
Mostaza, Jose M.
dc.contributor.author
Pérez-Martínez, Pablo
dc.contributor.author
Pintó, Xavier
dc.contributor.author
Salas-Salvadó, Jordi
dc.contributor.author
Valdivielso, Pedro
dc.identifier
https://ddd.uab.cat/record/211389
dc.identifier
urn:10.2147/DMSO.S165740
dc.identifier
urn:oai:ddd.uab.cat:211389
dc.identifier
urn:pmid:30464566
dc.identifier
urn:pmcid:PMC6217133
dc.identifier
urn:pmc-uid:6217133
dc.identifier
urn:articleid:11787007v11p683
dc.identifier
urn:scopus_id:85059008603
dc.identifier
urn:wos_id:000449066300001
dc.identifier
urn:altmetric_id:50500107
dc.identifier
urn:oai:egreta.uab.cat:publications/34e99523-facf-492c-a4e7-ec23ad7859fa
dc.identifier
urn:oai:pubmedcentral.nih.gov:6217133
dc.description.abstract
Metabolic syndrome (MetS), a disorder with a high and growing prevalence, is a recognized risk factor for cardiovascular disease (CVD) and type 2 diabetes. It is a constellation of clinical and metabolic risk factors that include abdominal obesity, dyslipidemia, glucose intolerance, and hypertension. Unfortunately, MetS is typically underrecognized, and there is great heterogeneity in its management, which can hamper clinical decision-making and be a barrier to achieving the therapeutic goals of CVD and diabetes prevention. Although no single treatment for MetS as a whole currently exists, management should be targeted at treating the conditions contributing to it and possibly reversing the risk factors. All this justifies the need to develop recommendations that adapt existing knowledge to clinical practice in our healthcare system. In this regard, professionals from different scientific societies who are involved in the management of the different MetS components reviewed the available scientific evidence focused basically on therapeutic aspects of MetS and developed a consensus document to establish recommendations on therapeutic goals that facilitate their homogenization in clinical decision-making.
dc.format
application/pdf
dc.relation
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy ; Vol. 11 (october 2018), p. 683-697
dc.rights
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
dc.rights
https://creativecommons.org/licenses/by-nc/4.0/
dc.subject
Cardiovascular prevention
dc.subject
Diabetes prevention
dc.subject
Insulin resistance
dc.title
COSMIC project : consensus on the objectives of the metabolic syndrome in clinic
dc.type
Article de revisió